skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

THE EUROPEAN PHARMACOPOEIA IS WORKING ON GENERAL QUALITY STANDARDS FOR MABS

THE EUROPEAN PHARMACOPOEIA IS WORKING ON GENERAL QUALITY STANDARDS FOR MABS

A pilot study on the setting of European quality standards for monoclonal antibodies is being expanded following the adoption of the first European Pharmacopoeia MAb monograph, for infliximab, in November 2017. The aim of the pilot is to develop horizontal quality standards applicable to MAbs in general, according to the European Directorate for the Quality of Medicines and Healthcare Products (EDQM).

The project was initiated in 2014 in view of a growing demand for further quality standards for biotherapeutics, and following “extensive consultation” with stakeholders, says the EDQM, which publishes the European Pharmacopoiea. A “bottom-up approach” has been taken, moving progressively from specific (individual) monographs to general texts applicable to MAbs, it says.

To kick off the pilot phase, infliximab was chosen as a case study to demonstrate the feasibility of establishing an individual monograph for a complex MAb. The adoption of the infliximab monograph by the Pharmacopoeia Commission in November last year marked “a significant milestone in setting quality standards for complex biotherapeutics,” according to the EDQM. The monograph will become effective in January 2019.

“The experience gained during the elaboration of the infliximab monograph will now serve as a basis for the development of horizontal standards applicable to MAbs,” the directorate says. “Work is currently ongoing on the elaboration of general requirements and methodologies for potency determination for anti-TNF-alfa products, as well as for physico-chemical testing applied to various MAbs.”

Etanercept Monograph Implemented

The EDQM also reported that six European Pharmacopoeia monographs developed under a separate pilot project onbiotherapeutic quality standards have now taken effect, the latest one being for etanercept, which was adopted in November 2017 and implemented on July 1. The others are for insulin glargine, recombinant Factor VIIa, recombinant Factor IX (solution and powder for injection solution) and teriparatide.

The pilot on biotherapeutic monographs (P4-BIO), which began in 2008 and ended in November 2016, was initiated because of growing regulatory and industry interest in insulins and coagulation factors. It has shown that robust quality standards can be set for complex molecules and used in the development of biosimilar medicines as more biological drugs come off patent, according to the EDQM. (Also see "New European Monographs Set ‘Robust Standards’ For Biosimilar Development" - Pink Sheet, 11 Jan, 2017.) It says the initiative has become “an established mechanism within the Ph. Eur. framework for setting public standards for biotherapeutic proteins.”

In the case of biosimilars, the EDQM points out that monographs provide harmonized quality requirements for medicinal products throughout Europe, regardless of the regulatory procedure used for their marketing authorization.

If there is a monograph for a substance, “compliance with such a written standard is required,” it says. However, it stresses that monographs “are not intended to be used as reference medicinal products (comparators) for the demonstration of biosimilarity.” The European Medicines Agency's guideline on quality issues for biosimilars, it points out, “clearly states that comparison of the biosimilar to a publicly available standard, e.g., a pharmacopoeial monograph, is not sufficient for the purpose of comparability.”

More Flexibility

The EDQM also says that during the process of developing biotherapeutic monographs, it became clear that additional flexibility was needed to address the structural complexity and naturally occurring heterogeneity of these products, as well as the potential diversity of a compound resulting from different manufacturing processes.

As a result, tests related to process-dependent heterogeneity, such as glycosylation, were introduced in the production section of a number of monographs, including those for rDNA Factor VIIa solution, rDNA Factor IX solution, etanercept and infliximab.

In addition, in the case of complex test procedures and assays, an outline of a suitable test method (for example essential steps in the procedure) is typically given. This test can be used or it can be replaced by “another suitable, validated procedure without having to demonstrate its equivalence to the example method, subject to approval by the competent authority.”

European Pharmacopoeia monographs and reference standards “play a major role in ensuring the quality of biotherapeutics,” and are designed to meet the needs of all stakeholders, including the pharmaceutical industry, official medicines control laboratories and regulatory authorities, according to the EDQM.

The updated information on biotherapeutic quality standards can be found on a newly launched section of the EDQM’s website at www.edqm.eu/en/biotherapeutics.

From the editors of Scrip Regulatory Affairs.

 

 

お薦めの関連記事

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...

    医療用医薬品、医療機器、薬事規制ニュース配信サービス

    Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Pink Sheet: 世界の薬事規制と承認審査に関するニュース

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

または下記のフォームよりご連絡下さい。

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。